Cablivi and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Cablivi (caplacizumab-yhdp), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Prednisone, and have Thrombotic microangiopathy.

The phase IV clinical study analyzes which people have Weakness when taking Cablivi. It is created by eHealthMe based on reports of 1,147 people who have side effects when taking Cablivi from the FDA, and is updated regularly.

What is Cablivi?

Cablivi has active ingredients of caplacizumab-yhdp. eHealthMe is studying from 1,147 Cablivi users. Check the latest studies of Cablivi.

What is Weakness?

Weakness is found to be associated with 3,638 drugs and 6,617 conditions by eHealthMe. Check the latest studies of Weakness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 31, 2026

1,147 people reported to have side effects when taking Cablivi.
Among them, 30 people (2.62%) have Weakness.

Among these 30 people:

How long have people been on Cablivi when they have Weakness? *

What is the gender of people who have Weakness when taking Cablivi? *

female: 92.59 %
male: 7.41 %

What is the age of people who have Weakness when taking Cablivi? *

What are other drugs people take besides Cablivi? *

Trazodone Hydrochloride: 2 people, 6.67%
Seroquel: 2 people, 6.67%
Prednisone: 2 people, 6.67%
Rituxan: 1 person, 3.33%
Omeprazole: 1 person, 3.33%
Melatonin: 1 person, 3.33%
Lansoprazole: 1 person, 3.33%
Hydroxyzine: 1 person, 3.33%
Folic Acid: 1 person, 3.33%
Fluconazole: 1 person, 3.33%

What are other side effects people have besides Weakness? *

Fatigue (feeling of tiredness): 7 people, 23.33%
Adjustment Disorder With Depressed Mood: 7 people, 23.33%
Nosebleed (bleeding from nose): 5 people, 16.67%
Hospitalisation: 5 people, 16.67%
Gait Disturbance: 3 people, 10.00%
Platelet Count Abnormal: 3 people, 10.00%
Headache (pain in head): 3 people, 10.00%
Speech Disorder: 3 people, 10.00%
Joint Pain: 3 people, 10.00%
Rashes (redness): 3 people, 10.00%

What are the existing conditions these people have? *

Thrombotic Microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury): 18 people, 60.00%
Thrombotic Thrombocytopenic Purpura (a rare blood disorder characterized by clotting in small blood vessels of the body): 12 people, 40.00%
Thrombocytopenia (decrease of platelets in blood): 1 person, 3.33%
Anaemia Megaloblastic (disorder of abnormally large red blood cells): 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Cablivi and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cablivi:

Cablivi (1,147 reports)

Weakness treatments and more:

Weakness (586,877 reports)

Browse all side effects of Cablivi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,638 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,617 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on caplacizumab-yhdp (the active ingredients of Cablivi) and Cablivi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.